ArticleAdvanced healthcare materials2026
A Gas Phototheranostic Nanocomposite Integrates Photothermal Molecule With Thermal-Sensitive Nitric Oxide Donor for Anticancer Therapy.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Photothermal therapy (PTT) has emerged as a promising strategy for tumor treatment, owing to its exceptional treatment outcomes and spatiotemporal control. However, persistent challenges, such as high-energy laser-induced damage to surrounding tissue and induces a cascade of heat shock responses (HSRs) in tumor cells, collectively contribute to suboptimal therapeutic outcomes. In addition, single-modality treatment approaches often fail to attain optimal therapeutic efficacy. In this study, we designed a gas/PTT nanocomposite material (PTZSCN-NO NPs) that integrates the photothermal molecule phenothiazin-thiophen-dimethylfuran (PTZSCN) with a thermosensitive nitric oxide (NO) donor (S-nitroso-N-acetylpenicillamine, SNAP). Upon laser irradiation, PTZSCN generates heat for PTT and promotes the release of NO from SNAP, can inhibit the expression of multiple HSPs, thus enhancing the efficacy of PTT. Furthermore, upon light exposure, PTZSCN-NO NPs generate a photothermal effect, leading to mitochondrial damage, caspase-1 activation, and gasdermin D cleavage. These events ultimately induce pyroptosis, achieving a synergistic gas/photothermal therapeutic effect and suppressed orthotopic breast tumor growth and metastasis in a tumor-bearing mice model. This approach optimizes conventional PTT and providing a repeatable, noninvasive treatment process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.